The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 05, 2010
Filed:
Mar. 15, 2006
Oliver Schildgen, Cologne, DE;
Martin Vogel, Bonn, DE;
Bertfried Matz, Bonn, DE;
Juergen Rockstroh, Cologne, DE;
Rolf Kaiser, Bonn, DE;
Martin Daeumer, Bonn, DE;
Martin Helm, Nuernberg, DE;
Lutwin Weitner, Hamburg, DE;
Carl Knud Schewe, Hamburg, DE;
Wolfram Gerlich, Marburg, DE;
Oliver Schildgen, Cologne, DE;
Martin Vogel, Bonn, DE;
Bertfried Matz, Bonn, DE;
Juergen Rockstroh, Cologne, DE;
Rolf Kaiser, Bonn, DE;
Martin Daeumer, Bonn, DE;
Martin Helm, Nuernberg, DE;
Lutwin Weitner, Hamburg, DE;
Carl Knud Schewe, Hamburg, DE;
Wolfram Gerlich, Marburg, DE;
Rheinishche Friedrich-Wilhelms-Universitaet Bonn, Bonn, DE;
Universitaet Zu Koeln, Cologne, DE;
Justus-Liebig-Universitaet Gissen, Giessen, DE;
Abstract
The present invention relates generally to the field of Hepatitis B variants exhibiting a reduced sensitivity to nucleoside analogues both in vivo and in vitro. More in particular, reverse transcriptase mutant rt I233V is provided. Present invention provides assays and methods for detecting such variant, which assays are useful in monitoring anti-viral therapeutic regimes and adjusting patient therapy. A diagnostic kit for detecting the presence of an HBV variant in a biological sample has also been described. Finally, the use of a pharmaceutical composition to cure a subject suffering from a HBV infection, which HBV is resistant to lamuvidine and/or adefovir has been provided, which pharmaceutical composition comprises the nucleoside analogue tenofovir.